When was PeptiDream founded?

PeptiDream was founded in 2006 and raised its 1st funding round 2 years after it was founded.

Where is PeptiDream located?

PeptiDream is headquartered in Erimo, Japan.

How many employees does PeptiDream have?

As of Jul 01, 2024, the latest employee count at PeptiDream is 23.

Is PeptiDream a funded company?

PeptiDream is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 22, 2008.

When was the latest funding round of PeptiDream?

PeptiDream's latest funding was a $***** Grant (prize money) round on Nov 01, 2019, with participation from 1 investor.

Where does PeptiDream rank among its competitors?

PeptiDream ranks 396th amongst 3262 active competitors, of which 1121 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of PeptiDream?

PeptiDream's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

PeptiDream - 2026 Company Profile, Funding & Competitors

PeptiDream is a public company based in Erimo (Japan), founded in 2006. It operates as a Developer of peptide-based drugs for a broad range of indications. PeptiDream has raised an undisclosed amount in funding. The company has 3262 active competitors, including 1121 funded and 773 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Developer of peptide-based drugs for a broad range of indications. The company uses a proprietary PDPS (Peptide Discovery Platform System) Technology to develop small molecule drugs for Oncology, Multiple Myeloma, DMD/Muscle Disorders, influenza, and more.

Key Metrics

Founded Year

2006

Location

Erimo, Japan

Stage

Public

Latest Funding Round

Grant (prize money), Nov 01, 2019, $*****

Investors

Gates & 1 more

Ranked

396^th among 3262 active competitors

Employee Count

23 as on Jul 01, 2024

Investment & Acquisitions

LinqMed & 3 more

Similar Companies

Jazz Pharmaceuticals & 2976 more

Exit Details

Public

View PeptiDream's full profile

PeptiDream got listed on Jun 11, 2013.

Click here to take a look at PeptiDream's IPO in detail

PeptiDream has raised funding over 3 rounds. Its first funding round was on Jul 22, 2008. Its latest funding round was a Grant (prize money) round on Nov 01, 2019 for $*****. 1 investor participated in its latest round. PeptiDream has 2 institutional investors.

Here is the list of recent funding rounds of PeptiDream:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 01, 2019	7136623	Grant (prize money)	8322520	4200225	4694219	6103778
Nov 2017	2982256	Grant (prize money)	5682665	6221081	1717484	Gates
Jul 22, 2008	4764476	Series A	5704427	8234369	9008331	UTEC

Access funding benchmarks and valuations. Sign up today!

View details of PeptiDream's funding rounds and investors

PeptiDream's employee count trend

PeptiDream has 23 employees as of Jul 24. Here is PeptiDream's employee count trend over the years:

Uncover PeptiDream's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PeptiDream include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of PeptiDream, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
396th	PeptiDream 2006, Erimo (Japan), Public	Developer of peptide-based drugs for a broad range of indications	-	Gates, UTEC	55/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on PeptiDream's competitors? Click here to see the top ones

PeptiDream has not made any acquisitions yet. PeptiDream has made 4 investments.

Here is the list of latest three $investments:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 14, 2025	Investments	LinqMed	2022	Chiba (Japan)
Dec 22, 2023	Investments	LinqMed	2022	Chiba (Japan)
Nov 13, 2018	Investments	Kleo Pharmaceuticals	2015	New Haven (United States)